Key Stats for Tempus AI Stock
- Price change for Tempus AI stock: 24%
- $TEM Stock Price as of Aug. 19: $61
- 52-Week High: $104
- $TEM Stock Price Target: $63
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Tempus AI (TEM) stock had a huge day on Wednesday, jumping nearly 24%. The spark was positive Phase 3 trial results from the Merck-Moderna cancer vaccine collaboration.
That news mattered a lot to Tempus AI stockholders because the company has a pending $1.5 billion deal to acquire Personalis, which supplies the gene-sequencing technology behind Moderna’s cancer vaccine work. If the trial succeeds, that acquisition suddenly looks much more valuable.
This wasn’t just a one-day story, though. Tempus AI stock has been building momentum for weeks. On July 30, the company posted its first-ever quarterly GAAP net profit of $5.6 million, a big turnaround from a $42.8 million loss in the same quarter last year.
Revenue came in at $382.5 million, up 22% year-over-year. Management also raised its full-year 2026 revenue forecast to between $1.595 billion and $1.605 billion, with Adjusted EBITDA expected near $65 million.
There’s more behind the rally too.
On August 4, a peer-reviewed study in Nature Medicine backed up the accuracy of Tempus AI’s PRISM2 platform for cancer diagnosis and outcome prediction.
Two days later, the company announced a new partnership with CellCarta, making Tempus a commercial lab partner in its oncology diagnostics network.
On top of that, Tempus AI’s data licensing business grew 36% year over year, with deals from major pharma names like Merck and Gilead.
See analysts’ growth forecasts and price targets for Tempus AI stock (It’s free) >>>
What the Market Is Telling Us About Tempus AI Stock
A big piece of Wednesday’s move came from heavy short interest.
More than 26% of Tempus AI stock’s available float was sold short heading into the rally. When a heavily shorted stock jumps, short sellers often have to buy shares back to close their positions, and that buying adds even more fuel to the rally.
That’s a big reason the stock’s gain looks so outsized compared to the rest of the market; the S&P 500 only rose 0.4%, and the Nasdaq gained 0.1% the same day.
Wall Street’s overall view on Tempus AI stock remains a Moderate Buy, based on eight Buy ratings and seven Hold ratings over the past three months.
The average price target of $62.64 suggests only about 4% more upside from here, which means a lot of the good news may already be priced in.
Taken together, the market seems to be treating this as more than just excitement over one clinical trial. A first profitable quarter, growing data deals, and now a stronger case for the Personalis deal all point to real business progress, not just a short squeeze.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Tempus AI Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
